文献速递中医内科中药与中成药合理使用

银屑病临床异质性与中医药预测疗效:多中心真实世界研究

Clinical heterogeneity in psoriasis and the predictive efficacy of traditional Chinese medicine: A multi-center real-world study.
PubMed 文献 · J Integr Med · 2026-07-14

该多中心真实世界研究纳入银屑病患者,分为血热证、血瘀证和非血热/血瘀证,接受辨证口服中药治疗。结果发现三组PASI评分下降相似(P=0.07),但血瘀证组DLQI和瘙痒VAS改善更优(均P<0.05),基线PASI、女性、基线VAS和BMI是PASI改善的预测因素。

要点

  • 血热证与血瘀证患者人群特征及共病负担存在差异。
  • 8周辨证中药治疗对三组PASI改善相似,血瘀证组生活质量与瘙痒改善更优。
  • 基线PASI、女性、基线VAS和BMI可预测PASI改善。

核心结论

  • 辨证中药治疗可改善不同证型银屑病患者的病情,且血瘀证组在生活质量和瘙痒方面改善更优。

研究设计与样本

  • 多中心真实世界研究,纳入血热证689例、血瘀证319例、非血热/血瘀证349例银屑病患者,收集 demographics、生活方式、共病、疾病严重度和中医体质等数据。

主要发现

  • 血热证患者更年轻、受教育程度更高,血瘀证患者更喜辛辣食物、吸烟更多且共病负担更重。
  • 治疗8周后三组PASI评分下降相似(P=0.07),阴阳和平体质比例增加相似。
  • 血瘀证组皮肤病生活质量指数(DLQI)和瘙痒视觉模拟量表(VAS)评分改善更优(均P<0.05)。
  • PASI改善的预测因素包括基线PASI评分(β=0.59,P<0.001)、女性(β=0.57,P=0.004)、基线VAS评分(β=0.11,P=0.02)和体重指数(β=-0.08,P=0.007),可解释58.9%的结局变异(R²=0.589)。
  • 治疗相关不良事件发生率为3.54%,第16周复发率低于5.02%。

临床怎么用

  • 临床可依据血热证与血瘀证的不同特征进行辨证,血瘀证患者可能从治疗中获得更好的生活质量和瘙痒改善。
  • 基线PASI、性别、基线VAS和BMI可用于预测PASI改善,辅助个体化治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This multi-center, real-world study aimed to characterize the clinical profiles of different traditional Chinese medicine (TCM) syndromes and assess the associated treatment outcomes, including efficacy, safety, and predictive factors. METHODS: Psoriasis patients with blood-heat syndrome (BHS), blood-stasis syndrome (BSS) and non-BHS/BSS were included. Data on demographics, lifestyle, comorbidities, disease severity, and TCM constitutions were collected. Patients received syndrome-specific oral Chinese herbal medicines. Multiple linear regression identified efficacy predictors for the reduction in psoriasis area and severity index (PASI) scores at week 8. RESULTS: This study included 689 psoriasis patients with BHS, 319 with BSS, and 349 with non-BHS/BSS. BHS patients were younger and more highly educated, while BSS patients preferred spicy food, smoked more, and carried a heavier comorbidity burden. Following 8 weeks of treatment, all groups showed similar reductions in PASI scores (P = 0.07) and comparable increases in the proportion of participants with the yin-yang harmony constitution. Patients in the BSS group, however, had a superior improvement in their dermatology life quality index (DLQI) score and their visual analog scale (VAS) score for pruritus (all P < 0.05). Key predictors of PASI improvement included baseline PASI score (β = 0.59, P < 0.001), female sex (β = 0.57, P = 0.004), baseline VAS score (β = 0.11, P = 0.02) and body mass index (β = -0.08, P = 0.007), explaining 58.9% of the outcome variance (R2 = 0.589). Treatment-related adverse events occurred in only 3.54% of cases and recurrence rates at week 16 remained below 5.02%. CONCLUSION: This study has not only clarified syndrome heterogeneity and validated the treatment system but also laid the groundwork for probing into the biological underpinnings of TCM syndromes. Please cite this article as: Sun XY, Zhou YQ, Liu L, Wei L, An YP, Weng HL, Ji YR, Guo S, Zhou WL, Hu WT, Wang JF, Fang YM, Zhao YD, Li JW, Zhu KB, Hu RY, Hu SY, Hu CX, Liang N, Yang CY, Jing FY, Zhang Y, Li X, Li B. Clinical heterogeneity in psoriasis and the predictive efficacy of traditional Chinese medicine: A multi-center real-world study. J Integr Med. 2026; Epub ahead of print.

来源:J Integr Med,查看原文。版权归原作者所有。

引用

  1. Sun XY, Zhou YQ, Liu L, et al. Clinical heterogeneity in psoriasis and the predictive efficacy of traditional Chinese medicine: A multi-center real-world study. J Integr Med. 2026. PMID: 42527213. doi:10.1016/j.joim.2026.07.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。